Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.16 | 0.03 | 0.03 |
| FCF Yield | -27.18% | -10.79% | -43.56% | -16.90% |
| EV / EBITDA | -3.72 | -5.33 | -2.47 | -4.43 |
| Quality | ||||
| ROIC | -120.66% | -64.62% | -61.12% | -59.42% |
| Gross Margin | 50.71% | 47.05% | 61.20% | 69.04% |
| Cash Conversion Ratio | 0.56 | 0.48 | 0.85 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.79% | -3.30% | -12.22% | -19.51% |
| Free Cash Flow Growth | -63.77% | 48.88% | 22.13% | 15.77% |
| Safety | ||||
| Net Debt / EBITDA | -1.55 | -1.15 | -0.58 | 0.60 |
| Interest Coverage | -23.81 | -34.28 | -63.80 | -284.68 |
| Efficiency | ||||
| Inventory Turnover | 0.24 | 0.27 | 0.14 | 0.05 |
| Cash Conversion Cycle | 255.14 | 278.31 | 584.11 | 1,232.37 |